[Comments on the current trends in virus research and the society].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to S Ujiie.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Since zinc is essential for the proliferation of tumor cells, the growth of tumor cells is suppressed in the zinc deficient condition. Thus, administration of progesterone, which decreases zinc uptake of tumor cells, to tumor bearing rats may inhibit the tumor growth. From this aspect, the antitumor effect of progesterone alone, or in combination with various anticancer drugs was investigated in the rats bearing Yoshida sarcoma (YS) or ascites hepatoma 109A (AH 109 A). In YS bearing rats, a significant inhibition of the tumor growth in size was observed by progesterone, and a slight inhibition of the tumor growth in AH 109 A bearing rats. A decreased zinc content of YS cells was also observed in YS bearing rats given progesterone in comparison with that of control rats. In combination of progesterone and anticancer drugs, the antitumor effect of methotrexate or vincristine was markedly enhanced by progesterone in YS bearing rats.
The serum Zn content in rats bearing Yoshida-Sarcoma, AH 66F, AH 13 or AH 109A was found to be low as compared with that in normal controls. In the rats which had received intraperitoneal inoculum of Yoshida-Sarcoma, the effects of anticancer drugs were closely related to the changes in serum Zn content. Namely, serum Zn content increased and approached the normal range almost parallel with the prolongation of survival time by anticancer drugs. As the causes responsible for the reduction in quantity of serum Zn in the tumor-bearing rats, the reduction of serum albumin content and the accumulation of Zn in the tumor tissue and organs such as the liver and kidneys were suggested.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.